VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer
NCT ID: NCT05540951
Last Updated: 2022-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
78 participants
INTERVENTIONAL
2018-06-01
2022-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer
NCT04215731
Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
NCT05111860
A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer
NCT03245203
Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer
NCT07333053
Neoadjuvant mFOLFOXIRI Chemotherapy Alone for Extramural Vascular Invasion Positive Locally Advanced Rectal Cancer
NCT04170530
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VIC
VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
VIC
VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
BEV
Bevacizumab Plus Chemotherapy
Bevacizumab Plus Chemotherapy
Bevacizumab Plus Doublet or Triplet Chemotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VIC
VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
Bevacizumab Plus Chemotherapy
Bevacizumab Plus Doublet or Triplet Chemotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed colorectal adenocarcinoma
* Histologically confirmed BRAFV600E mutated and RAS wild-type
* Initially unresectable metastatic or local CRC
* ECOG performance status of 0-1 and life expectancy ≥3 months
* adequate hepatic, renal, and hematologic function
Exclusion Criteria
* Other cancers (with the exception of cervical cancer in situ and squamous cell carcinoma of the skin) within the previous 5 years.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xu jianmin
Deputy director of the department of general surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of General Surgery, Zhongshan Hospital, Fudan University
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VICBEV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.